Looking ahead to 2014, we feel better about the health of our core academic and government customers and about our prospects in the clinical research and diagnostics markets, but we remain cautious about demand from the industrial markets. Overall, we expect to generate year-over-year revenue growth of approximately 3 to 4 percent, and non-GAAP EPS growth of 10 to 14 percent, for the full year 2014.BRKR closed yesterday (02014.02.18) at $21.86. 52-week range: $15.41 - $22.25. At its current price BRKR has a PSR (Price Sales Ratio) of 2, which I think is low for a company that makes equipment that scientists use to create our future.
Five minutes into trading today (02014.02.19) BRKR is at $23.25 (up ~6.4%) after spiking to a new 52-week high of $23.59.
No comments:
Post a Comment